GH

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Wall Street analysts forecast GH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 92.84 USD with a low forecast of 60.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Guardant Health Inc revenue for the last quarter amounts to 265.20M USD, increased 38.50 % YoY.

Guardant Health Inc. EPS for the last quarter amounts to -0.74 USD, decreased -15.91 % YoY.

Guardant Health Inc (GH) has 1999 emplpoyees as of December 15 2025.

Today GH has the market capitalization of 13.21B USD.